This chapter defines a shared vocabulary for understanding medical technology ventures. It clarifies medical innovation across medical devices, in vitro diagnostics, and digital health solutions. The notion of startup failure is refined, distinguishing true failure—when expected returns cannot be achieved—from strategic pivots that enable learning. The chapter explains the differences between precision and accuracy in a company’s valuation, highlighting how both entrepreneurial optimism and decision biases might distort these delicate estimations. It differentiates marginal improvements from innovative ideas, underlining that true innovation drives clinical and economic transformation. Finally, it links investigation and decision-making within the Stage-Gate Model and introduces scenario decisions as assumption-based choices guiding strategic direction. A shared vocabulary supports the alignment of understanding among entrepreneurial stakeholders, which is particularly important in business environments characterized by high degrees of uncertainty, where environmental complexities and fast-changing assumptions often lead to misunderstandings and inefficiencies. It is therefore essential to establish a shared understanding of the fundamental concepts and their corresponding names.